Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GP20101
- Development stage
- Unknown
- Lead developer
- Geropharm
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
GP20101 is a biosimilar candidate of ranibizumab (Lucentis), developed by the Russian pharmaceutical company Geropharm. It is a recombinant humanized monoclonal antibody fragment (Fab) produced in *Escherichia coli* that binds to and inhibits vascular endothelial growth factor A (VEGF-A). By neutralizing VEGF-A, GP20101 prevents the activation of VEGFR1 and VEGFR2 receptors on the surface of endothelial cells, thereby inhibiting the abnormal proliferation of blood vessels (angiogenesis) and reducing vascular permeability in the retina. The drug is primarily being developed for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and other retinal vascular disorders. It is currently in Phase 3 clinical development to demonstrate therapeutic equivalence, safety, and immunogenicity compared to the reference product.
- Brand names
- Gepranib
- Other names
- ranibizumab biosimilarGeropharm ranibizumab
02
Targets
Beyond the preview
Go deeper on GP20101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GP20101.